ERBB2 and breast cancer: Of the 460 patients included in the primary analyses 61 (13%) were classified as having basal-like, 120 (26%) as Her2-enriched, 161 (35%) as luminal A and 116 (25%) as luminal B breast cancer, reflecting the population including patients with ER+/− and Her2+/− breast cancer.